A dual recombinant strategy to quantify PreS1 antibody in hepatitis B patients with genotype B or C virus by ELISA Authors: Yumin Li, Xiaoyu Wen, Jing Zhan, Tingting Cao, Xiumei Chi, Huanyi Cheng, Qingrui Huang, Wenyi Zhang, Junqi Niu, Huan Du, Zhenning Liu Published: 2026 ABSTRACT SummaryElevated levels of anti-preS1 antibodies in patients correlate with faster hepatitis B virus (HBV) clearance, since preS1 is vital for viral entry. However, accurate quantification of preS1 antibodies is hindered by the variation of HBV genotypes. Herein, a quantitative preS1 antibody assay was developed for Chinese patients with predominant HBV genotypes B and C. First, to address genotype diversity, we constructed a dual recombinant protein combining genotype B and C preS1. Second, a mouse-human chimeric antibody with high and comparable affinity for both B and C preS1 is developed as the standard for quantification by screening and cloning. An optimized ELISA kit using these components demonstrated good specificity, accuracy, reproducibility and stability, with a linear range of 10–100 ng/mL. This approach extends the patient coverage in China to over 95%, providing a valuable diagnostic tool. This work demonstrates a proof-of-concept model for developing broad-coverage assays for other multi-genotype viral diseases. Introduction Hepatitis B virus (HBV) infection is a major cause for the development of hepatocellular carcinoma (HCC) in China, which is often due to persistent viral replication within hepatocytes and associated immune responses.1,2,3,4 The envelope of HBV contains three surface proteins, among which the large surface protein (LHBs) possesses a unique preS1 region that forms the viral protrusion and mediates viral binding and entry into host cells.5,6,7,8 Antibodies targeting the preS1 region can neutralize HBV and block infection.9,10,11,12,13 More importantly, higher serum level of preS1 antibodies correlates with faster clearance of hepatitis B surface antigen (HBsAg), suggesting that the level of preS1 antibody may be used as an early serological indicator for the resolution of infection.14,15,16 Thus, compared with conventional quantitative measurements of HBsAg and HBV DNA, quantification of HBV preS1 antibodies in patients may not only reflect the direct immune response against the virus but also provides valuable information for assessing the stage of the disease and prognosis.17 Currently, ten HBV genotypes (A–J) have been identified, with genotypes B and C dominating in East Asia.18,19,20,21 In China, over 95% of hepatitis B patients are infected by HBV of genotype B or C, with genotype B being more prevalent in the south China and genotype C in the north.22,23,24 The sequence of preS1 region exhibits high variability across different HBV genotypes, leading to genotype-specific immune responses in patients.25,26 Unfortunately, previous kits for preS1 antibody did not account for the genotypic variation, which could result in false-negative outcomes and compromised detection accuracy when used to detect HBV of mismatched genotypes.27,28 Therefore, developing a quantitative assay for HBV preS1 antibody with broader genotype coverage will significantly improve the reliability of diagnosis and prognosis of hepatitis B. In this work, we first engineered a recombinant protein combining the HBV preS1 regions (B-C-preS1) of both genotypes B and C, two most common genotypes in China. Then, we developed a mouse-human chimeric antibody (HB2) targeting the preS1 region of HBV, which recognizes epitopes representing both genotypes B and C. Next, we constructed an enzyme-linked immunosorbent assay (ELISA) kit for quantitative detection of preS1 antibody in patient sera. The assay employs recombinant B-C-preS1-coated microplates to capture preS1 antibodies from patients infected with HBV of either genotype B or C, while horseradish peroxidase (HRP)-conjugated anti-human IgG is applied as the detection antibody. The chimeric HB2 antibody is used as the standard for quantification. We have validated the performance of this ELISA kit in quantifying preS1 antibodies in Chinese patient sera, demonstrating the effectiveness for this dual recombinant strategy of joining proteins of different genotypes. Results Preparation of dual recombinant B-C-preS1 Dual recombinant B-C-preS1 protein was prepared according to the procedure shown in Figure 1A. HBV DNA was isolated from the sera of patients infected with genotype B or C HBV and subsequently amplified by PCR to obtain DNA fragments coding for genotype B or C preS1. Gel electrophoresis exhibited a band at approximately 1,200 bp for each fragment (Figure S1). After these two fragments were connected by overlapping PCR, a DNA band of approximately 2,400 bp was observed on the gel (Figure 1B). The DNA fragment coding for B-C-preS1 was cloned into the pcDNA3.1(−) vector and the recombinant plasmid was amplified in DH5α. The plasmid was extracted and digested by restriction enzymes for verification. Two DNA bands were observed at approximately 5,000 bp and 2,400 bp (Figure S2), representing the vector and the fragment coding for B-C-preS1, respectively.Figure 1Preparation and characterization of mouse-human chimeric pres1 antibody (HB2)(A) Schematic illustration for the development of recombinant B-C-preS1 protein and mouse-human chimeric preS1 antibody (HB2). HSA-KA-B-F, human serum albumin-Lys and Ala-B-forward primer; linker-StrepII-tag-B-R, linker-StrepII-tag-B-reverse primer; linker-C-F, linker-C-forward primer; His6-tag-C-R, His6-tag-C- reverse primer; overlap-F, overlap-forward primer; overlap-R, overlap-reverse primer; HB2 VL, HB2 variable domain of ight chain; HB2 VH, HB2 variable domain of heavy chain.(B) The image of DNA electrophoresis for B-C-preS1. M: DNA marker; Lane B + C: DNA for B-C-preS1.(C) The Coomassie blue staining image of B-C-preS1 protein by SDS-PAGE. M: protein maker; Lane 1: purified B-C-preS1 protein.(D) SDS-PAGE image of HB2 antibody. M: protein marker; Lane 1: HB2 (2 μg) reduced by DTT; Lane 2: HB2 (2 μg) without DTT.(E) The verification of the cross-reactivity of HB2 with B-C-preS1, B-preS1, and C-preS1. Data are presented as mean ± SD (n = 3 replicates). Preparation and characterization of mouse-human chimeric pres1 antibody (HB2) (A) Schematic illustration for the development of recombinant B-C-preS1 protein and mouse-human chimeric preS1 antibody (HB2). HSA-KA-B-F, human serum albumin-Lys and Ala-B-forward primer; linker-StrepII-tag-B-R, linker-StrepII-tag-B-reverse primer; linker-C-F, linker-C-forward primer; His6-tag-C-R, His6-tag-C- reverse primer; overlap-F, overlap-forward primer; overlap-R, overlap-reverse primer; HB2 VL, HB2 variable domain of ight chain; HB2 VH, HB2 variable domain of heavy chain. (B) The image of DNA electrophoresis for B-C-preS1. M: DNA marker; Lane B + C: DNA for B-C-preS1. (C) The Coomassie blue staining image of B-C-preS1 protein by SDS-PAGE. M: protein maker; Lane 1: purified B-C-preS1 protein. (D) SDS-PAGE image of HB2 antibody. M: protein marker; Lane 1: HB2 (2 μg) reduced by DTT; Lane 2: HB2 (2 μg) without DTT. (E) The verification of the cross-reactivity of HB2 with B-C-preS1, B-preS1, and C-preS1. Data are presented as mean ± SD (n = 3 replicates). The recombinant plasmid was transfected into HEK293F cells for protein expression. The SDS-PAGE of the purified recombinant B-C-preS1 protein showed a single band of approximately 100 kDa (Figure 1C). Western blotting with two previously reported genotype-specific antibodies29 indicates that B-C-preS1 indeed cross-reacts with HBV genotype B and C antibodies against preS1 (Figure S3). Preparation of mouse-human chimeric preS1 antibody (HB2 antibody) A mouse-human chimeric preS1 antibody was developed as the standard for the quantitative measurement of HBV preS1 antibody in patient sera (Figure 1A). Specifically, Balb/c mice were immunized with B-C-preS1, and preS1-specific antibody levels were titrated by ELISA with B-preS1-coated plates, C-preS1-coated plates and B-C-preS1-coated plates (Figure S4). The mice were sacrificed when the optical density (OD) values of mouse sera could still exceed that of the negative control after 1:108 dilution. The serum of mouse 1 (#1) exhibited high and comparable reactivity on B-preS1-coated plates, C-preS1-coated plates and B-C-preS1-coated plates, which had the same amount of coated protein. Therefore, peripheral blood mononuclear cells (PBMCs) were isolated from the blood of mouse 1 for B cell sorting with FITC-labeled B-C-preS1 and PE-conjugated anti-mouse CD19 antibody (Figure S5). FITC and PE double-positive B cells were isolated for RNA extraction. The extracted RNA was reverse-transcribed to generate cDNA, which was subsequently used as the template for PCR amplification. The amplified DNA fragments were cloned into the pcDNA3.1 (−) vector containing human IgG1 Fc for expression in HEK293F cells. The supernatants containing expressed antibodies were screened to identify an antibody named as HB2 that cross-reacted with genotype B and C preS1. The sequences of the variable region of HB2 antibody are shown in Table S1. The SDS-PAGE revealed a single band for the purified HB2 antibody without DTT reduction, whereas two distinct bands appeared at approximately 50 kDa and 25 kDa after DTT reduction (Figures 1D and S6). The cross-reactivity of HB2 was verified against B-preS1, C-preS1, and B-C-preS1 by ELISA (Figure 1E). To our delight, HB2 shows comparable reactivity with B-preS1, C-preS1, and B-C-preS1. The EC50 values for the HB2 antibody to detect B-C-preS1, B-preS1, and C-preS1 are 177.27 ng/mL, 177.71 ng/mL, and 179.86 ng/mL, respectively. Subsequently, we determined the binding affinity of HB2 antibody to B-C-preS1 by surface plasmon resonance (SPR). Within the concentration range of 12.5–6,400 nM, HB2 antibody can induce a significant binding response with the B-C-preS1 (Figure S7). The response signal gradually intensifies as the concentration of HB2 antibody increases, demonstrating a typical concentration-dependent binding characteristic. The KD value (1.90 × 10−7 M) indicates that there is a strong binding affinity between HB2 antibody and B-C-preS1. The kd value (1.25 × 10−3 s−1) suggest that the complex dissociates slowly, indicating that the two molecules have high stability after binding. The purity of HB2 antibody was assessed by size exclusion chromatography-high performance liquid chromatography (SEC-HPLC). Three peaks were observed at retention times of approximately 9.39, 11.49, and 16.90 min (Figure S8), corresponding to high-molecular-weight aggregates, monomer, and low-molecular-weight fragments, respectively. The peak of monomer was predominant, accounting for >95% of the total species, indicating a high purity for HB2 antibody. Optimization of the quantitative ELISA kit for HBV preS1 antibody We systematically optimized the ELISA conditions and successfully established a quantitative measurement for HBV preS1 antibody. Figure 2A illustrates the simplified preparation and detection procedure including antigen coating (1), blocking (2), incubation with the standard (HB2) and patient sera (3), detection with HRP-conjugated anti-human IgG antibody (4), and finally incubation with substrates and plate reading. Our efforts centered on a four-step process to refine both the preparation and detection protocols for the ELISA kit.Figure 2Optimization of the quantitative ELISA kit for HBV preS1 antibody(A) Schematic illustration of the preparation and detection of the quantitative ELISA kit for HBV preS1 antibody. BSA: bovine serum albumin; GS: goat serum.(B) Checkerboard titration for the concentration of B-C-preS1 and the dilution of HRP-conjugated anti-human IgG antibody.(C) Coating buffer optimization.(D) Coating time and temperature optimization.(E) Blocking solution optimization.(F) Optimization of blocking time at 37 °C for b4.(G) Sample dilution buffer optimization.(H) Incubation time optimization for HB2 diluted in s9 at 37°C.(I) Optimization of the dilution buffer for HRP-conjugated anti-human IgG antibody.(J) Optimization of the incubation time with HRP-conjugated anti-human IgG antibody at 37 °C. Data are the mean values of triplicated experiments. P, positive; N, negative. P/N values are calculated from means. Data are presented as mean ± SD (n = 3 replicates). Optimization of the quantitative ELISA kit for HBV preS1 antibody (A) Schematic illustration of the preparation and detection of the quantitative ELISA kit for HBV preS1 antibody. BSA: bovine serum albumin; GS: goat serum. (B) Checkerboard titration for the concentration of B-C-preS1 and the dilution of HRP-conjugated anti-human IgG antibody. (C) Coating buffer optimization. (D) Coating time and temperature optimization. (E) Blocking solution optimization. (F) Optimization of blocking time at 37 °C for b4. (G) Sample dilution buffer optimization. (H) Incubation time optimization for HB2 diluted in s9 at 37°C. (I) Optimization of the dilution buffer for HRP-conjugated anti-human IgG antibody. (J) Optimization of the incubation time with HRP-conjugated anti-human IgG antibody at 37 °C. Data are the mean values of triplicated experiments. P, positive; N, negative. P/N values are calculated from means. Data are presented as mean ± SD (n = 3 replicates). As shown in Figure 2B, the checkerboard titration for the concentration of B-C-preS1 (the coating antigen) and the dilution of HRP-conjugated anti-human IgG antibody (the detection antibody) revealed a highest P/N ratio at 2 μg/mL for the coating antigen and 1:2,00000 dilution for the detection antibody, among the examined combinations. It is known that the binding capacity of antigen to the plate is influenced by the pH and ionic strength of the coating buffer. The P/N ratio increased as the ionic strength of carbonate-buffered saline (CBS) increased at the same pH of 9 (Figure 2C), suggesting that higher ionic strength facilitated antigen coating within the tested range. Meanwhile, the pH of coating buffer seemed to play a more important role and a highest P/N ratio was obtained when 1 × PBS (pH = 8.0) was used as the coating buffer (Figure 2C). The optimal coating condition of this buffer was determined as overnight at 4 °C (Figure 2D). After coating, the plates were blocked with 10 blocking solutions (b1-b10) to reduce nonspecific signals. It is found the b4 combination of 4% sucrose and 8% GS yielded a higher P/N ratio than the others (Figure 2E). Hence, the blocking solution was chosen as 1 × PBS containing 0.2% BSA, 0.25% Tween 20, 4% sucrose, and 8% GS. Subsequently the optimal blocking condition was determined as 2 h at 37 °C (Figure 2F). Dilution buffers for sample and HRP-conjugated anti-human IgG antibody also affect the accuracy and stability of the ELISA kit. 15 sample dilution buffers (s1-s15) were tested and the optimal sample dilution buffer is s9, which is 1 × PBS containing 0.1% Proclin300, 0.25% Tween 20 and 8% GS (Figure 2G). The optimal duration for the incubation of diluted samples at 37 °C was chosen as 0.5 h (Figure 2H). NaCl was added to the optimal sample dilution buffer (s9) to make the dilution buffer for HRP-conjugated anti-human IgG antibody. It is found that s9 with 8% NaCl has a better P/N ratio than the others (Figure 2I) and the optimal incubation time at 37 °C is 0.5 h (Figure 2J). Performance of the quantitative ELISA kit for HBV preS1 antibody We first determined the linear range and detection limit of our quantitative ELISA kit for HBV preS1 antibody. Then we examined the reproducibility, accuracy and cross-reactivity of the ELISA kit to evaluate the performance. The measurement of a serial dilution of the HB2 antibody with our home-made ELISA kit yielded a linear standard curve with R2 = 0.9939 (Figure 3A), indicating a good linearity. The linear range of the standard curve is 8.78–100 ng/mL. So, the quantitative detection limit of the ELISA kit is determined as 10–100 ng/mL with the consideration of variance.Figure 3Serum tests with ELISA kits for preS1 antibody(A) OD values for a serial dilution of HB2 antibody.(B) Optimization of sample dilution ratio.(C) Results of 156 positive sera (patients) and 66 negative sera (healthy individuals) with the home-made quantitative ELISA kit (The average OD values are 0.046 for healthy individuals and 0.49 for positive sera. The standard deviations are 0.016 and 0.23, respectively).(D) ROC curve of the ELISA kit. AUC, area under curve.(E) Results of 156 positive sera by a commercial kit and the home-made ELISA kit.(F) Cross-reactivity tests. Data for (A and F) are presented as mean ± SD (n = 3 replicates). The sample size in B, C, D, and E is 1. Significance for the differences were determined by one-way ANOVA. The significance level was α = 0.05, and p values are reported: p value <0.05 demonstrates significance; p value <0.01 demonstrates high significance; p value <0.001 demonstrates very high significance. Serum tests with ELISA kits for preS1 antibody (A) OD values for a serial dilution of HB2 antibody. (B) Optimization of sample dilution ratio. (C) Results of 156 positive sera (patients) and 66 negative sera (healthy individuals) with the home-made quantitative ELISA kit (The average OD values are 0.046 for healthy individuals and 0.49 for positive sera. The standard deviations are 0.016 and 0.23, respectively). (D) ROC curve of the ELISA kit. AUC, area under curve. (E) Results of 156 positive sera by a commercial kit and the home-made ELISA kit. (F) Cross-reactivity tests. Data for (A and F) are presented as mean ± SD (n = 3 replicates). The sample size in B, C, D, and E is 1. Significance for the differences were determined by one-way ANOVA. The significance level was α = 0.05, and p values are reported: p value <0.05 demonstrates significance; p value <0.01 demonstrates high significance; p value <0.001 demonstrates very high significance. In order to optimize the dilution factor for patient sera, 20 patient sera containing genotype B or C HBV virus were diluted 2, 5, 10, 20, and 40 times to a final volume of 100 μL and tested with the ELISA kits. At the dilution of 20-fold, most of OD values were within the linear detection range (Figure 3B). At the dilution of 10-fold, some OD values of patient sera exceeded the upper limit of the linear range, whereas at 40-fold dilution some OD values fell below the detection limit, resulting in false negatives. So, 20-fold dilution (5 μL patient serum to the final volume of 100 μL) was chosen for subsequent dilution of patient sera. Next, 20 sera of healthy individuals were tested with the home-made ELISA kit to decide the qualitative cut-off value, which was calculated as X¯ +2SD, where X¯ is the average OD value of healthy individual sera and SD stands for standard deviation. The calculated cut-off is 0.0775, which corresponds to the preS1 concentration of 7.62 ng/mL. It should be noted that this qualitative cut-off value is below the lower limit of the quantitative detection range. To evaluate the reproducibility, we tested the intra-assay and inter-assay variations with 3 patient sera on the same day using three batches of ELISA kits manufactured at different time. The coefficients of variation (CV) for intra-assay and inter-assay are shown in Table 1. The intra-assay coefficients of variation (CVs) of the three batches ranged from 5.89% to 8.88%, whereas the inter-assay CVs varied from 7.77% to 8.53%. Together, the intra- and inter-assay CVs for our home-made kit were both measured below 9%, a result well within and significantly exceeding the precision requirement (CV < 15%) stipulated by Chinese guidelines, indicating a satisfactory reproducibility.Table 1Intra-assay and inter-assay CVs for the home-made ELISA kitAssayIntra-assayInter-assayBatch 1Batch 2Batch 3SampleX¯± SDaCV%X¯± SDaCV%X¯± SDaCV%CV%P10.918 ± 0.0636.87%0.937 ± 0.0747.92%0.919 ± 0.0828.88%7.77%P20.380 ± 0.0225.89%0.333 ± 0.0247.16%0.360 ± 0.0267.26%8.53%P30.121 ± 0.0118.76%0.124 ± 0.0086.76%0.132 ± 0.0097.06%8.16%amean ± standard deviation, n = 3. Table 1Intra-assay and inter-assay CVs for the home-made ELISA kitAssayIntra-assayInter-assayBatch 1Batch 2Batch 3SampleX¯± SDaCV%X¯± SDaCV%X¯± SDaCV%CV%P10.918 ± 0.0636.87%0.937 ± 0.0747.92%0.919 ± 0.0828.88%7.77%P20.380 ± 0.0225.89%0.333 ± 0.0247.16%0.360 ± 0.0267.26%8.53%P30.121 ± 0.0118.76%0.124 ± 0.0086.76%0.132 ± 0.0097.06%8.16%amean ± standard deviation, n = 3. Intra-assay and inter-assay CVs for the home-made ELISA kit mean ± standard deviation, n = 3. A recovery experiment was conducted to evaluate the accuracy of our quantitative ELISA kit. First, three patient sera quantified with our home-made ELISA kit were chosen to represent high, medium and low levels of preS1 antibody. Then 2.5 μL of each serum, half of the dose (5 μL) used in the quantitative measurement, was mixed with a certain amount of HB2 antibody to yield a sample containing the expected level of preS1 antibody. The mixed samples were measured by our home-made ELISA kit again and the recovery rate was calculated as the ratio of measured level to expected level. The recovery rates ranged from 90.80% to 102.58% (Table 2), indicating a good accuracy of our home-made ELISA kit, especially for patient sera containing medium to high levels of preS1 antibody.Table 2Recovery rates for the patient sera mixed with HB2 antibodyMixed sampleExpected level (ng/mL)Measured level (ng/mL)Recovery rate (%)Mixed-high8079.6599.56Mixed-medium4041.03102.58Mixed-low2018.1690.80 Table 2Recovery rates for the patient sera mixed with HB2 antibodyMixed sampleExpected level (ng/mL)Measured level (ng/mL)Recovery rate (%)Mixed-high8079.6599.56Mixed-medium4041.03102.58Mixed-low2018.1690.80 Recovery rates for the patient sera mixed with HB2 antibody To determine the sensitivity of our home-made ELISA kit, 156 patient sera, confirmed by the commercial qualitative preS1 antibody kit from Shanghai Alpha, were used for PCR amplification of HBV DNA. The amplified fragments were sequenced for HBV genotyping, which identified 29 sera as genotype B and 127 sera as genotype C. These sera were tested by our home-made ELISA kit, as well as the sera from 66 healthy individuals (Figure 3C). All 156 patient sera were tested positive by our ELISA kit according to the qualitative cut-off, although 5 sera exceeded the upper limit of quantification range (>100 ng/mL). Meanwhile, the 66 sera of healthy individuals all yielded negative results below the qualitative cut-off. Hence, our ELISA kit shows high consistency with the commercial qualitative kit and the area under the receiver operating characteristic (ROC) curve area under curve (AUC) is 1 (Figure 3D). For comparison, a commercial quantitative kit for preS1 antibody from Shanghai Yueyan, but without the consideration of genotype specificity was used to measure the preS1 antibody level in these 156 positive sera (Figure 3E). Interestingly, the 127 sera of HBV genotype C were tested positive by the commercial kit, but the 29 sera of HBV genotype B were tested negative. Furthermore, the quantified results of HBV genotype C sera are in line with the preS1 antibody levels measured by our ELISA kit, which yielded a R2 of 0.9519. This comparative analysis suggests that our ELISA kit can not only quantify preS1 antibody in patients with high sensitivity, but also measure it with a broader patient coverage, i.e., patients with either genotype B or C HBV. Notably, such a patient coverage can better meet the clinical demand in China than the current commercial quantitative kit. The cross-reactivity of our ELISA kit was investigated with 4 other viruses including hepatitis A virus (HAV), hepatitis C virus (HCV), HBV-A, and HBV-D. Overall, the OD values for these 4 non-specific viruses are below the qualitative cut-off value (Figure 3F), indicating a low cross-reactivity of our ELISA kit with these examined viruses and suggesting a high specificity. Stability of the quantitative ELISA kit for HBV preS1 antibody Commercial application of our home-made ELISA kit requires a good stability. Thus, we comprehensively characterized its stability across four key scenarios: real-time storage stability, accelerated stability, in-use stability and simulated transportation stability. Each stability assessment was performed using a panel of five serum samples, comprising two from genotype B and three from genotype C. In order to test real-time storage stability, sealed kits of three batches were kept at 4 °C for 1 year and tested at the ends of month 3, 6, 9, and 12 (Figure 4A). The quantified preS1 antibody levels at the ends of month 9 and 12 were normalized to the respective readouts at month 0. The readout ratios of month 9/month 0 were in the range of 92.78%–100.05%, whereas the readout ratios for month 12 varied from 91.07% to 98.33%. These ratios are well above the required threshold of 80% in China, indicating that the sealed kit can be kept at 4 °C for at least 1 year.Figure 4Performance evaluation for the quantitative ELISA kit for HBV preS1 antibody(A) Real-time storage stability tests. M0–M12, month 0–month 12.(B) Accelerated stability tests. D0–D10, day 0–day 10.(C) In-use stability tests. D0–D7, day 0–day 7.(D) Simulated transportation stability tests. Data for (A, B, and C) are presented as mean ± SD (n = 3 replicates). Data for (D) are the mean values of triplicated experiments. Performance evaluation for the quantitative ELISA kit for HBV preS1 antibody (A) Real-time storage stability tests. M0–M12, month 0–month 12. (B) Accelerated stability tests. D0–D10, day 0–day 10. (C) In-use stability tests. D0–D7, day 0–day 7. (D) Simulated transportation stability tests. Data for (A, B, and C) are presented as mean ± SD (n = 3 replicates). Data for (D) are the mean values of triplicated experiments. To assess accelerated stability, unopened kits were stored at 37 °C for a period of 10 days, with performance testing conducted on days 0, 1, 3, 5, 7, and 10 (Figure 4B). PreS1 antibody levels measured on each day were normalized against their day 0 baselines. It is found that on day 7, the ratios of antibody levels ranged from 91.5% to 98.1%, indicating a good stability within one week at 37 °C. A small decline of readout was observed on day 10, when the readout of antibody level was 87.2% of the readout of day 0. To assess in-use stability, opened kits were stored at 4°C, with initial testing conducted on days 0, 3, 5, and 7 (Figure 4C). Again, following the same normalization procedure to day 0 baselines, the quantified preS1 antibody levels on day 7 yielded values between 90.6% and 100.1%. It should be mentioned that the readout ratios on day 5 are close to 100%, suggesting the unpacked kit can be kept at 4 °C for at least 5 days. To assess simulated transportation stability, kits from three batches first underwent 7-day shaking on a rocker at 60 r/min and were then subjected to three 1.5-meter drop tests, prior to stability assessment. No significant difference in the quantified preS1 antibody levels before and after the simulated transportation was observed (Figure 4D), indicating a good stability in transportation. Discussion The rapid mutation of viral genomes and the resulting genotypic diversity represent a prominent characteristic of many viruses, particularly RNA viruses and some highly variable DNA viruses.30 This genetic diversity not only facilitates viral immune escape, but also poses a persistent and serious challenge to viral detection.31,32 Both nucleic acid detection relying on specific primers/probes (e.g., PCR, sequencing) and protein detection based on antigen-antibody interactions (e.g., ELISA, immunochromatography) depend on the conservation of target sequences or epitopes.33 Mutations at key sites can lead to reduced efficiency or even complete failure of primer/probe binding, resulting in decreased detection sensitivity, false-negative outcomes, or failure to identify emerging variants. To address the challenge of viral detection, this work proposes and validates a straightforward yet effective general strategy: to construct a recombinant protein of tandemly expressed key proteins or antigenic regions from different viral genotypes as a broad-spectrum detection agent. We implemented this concept using the preS1 protein of HBV as a model. HBV is a DNA virus that involves reverse transcription in the life cycle, which leads to a relatively high genomic mutation rate. As a result, ten genotypes (A–J) of HBV have been reported with divergent sequences in the preS1 region, which imposes a challenge for a universal detection with high sensitivity.34,35 Through genetic engineering, we constructed a tandem expression plasmid containing representative preS1 sequences of two major HBV genotypes in China (genotypes B and C), and successfully purified the recombinant multi-genotype preS1 fusion protein (B-C-preS1). Experimental results demonstrate that, compared with conventional detection reagents of a single genotype preS1, the dual recombinant protein developed in this work exhibits significant advantages across multiple dimensions: First, it enables the development of cross-genotype antibodies (HB2 in our case). Antibodies generated by using this fusion protein as the immunogen can simultaneously recognize HBV preS1 proteins of both genotypes B and C. The principle lies in the tandem structure physically assembling characteristic epitopes from different genotypes in a single molecule, thereby providing binding sites with a broader recognition spectrum. Second, it substantially improves the patient coverage of ELISA detection. By presenting a multi-genotype protein, the dual recombinant strategy overcomes missed detection due to genotype variation. Our comparative test confirms that the commercial kits with a single preS1 genotype are inaccurate for patient samples with genotype B HBV (Figure 3E), which account for roughly 19% of the total, whereas our ELISA kit yields stable detection results across both genotype B and C patient samples. Third, it simplifies the production and detection process. Conventional multi-genotype detection approaches may require mixing multiple single-genotype proteins or conducting multiple genotype-specific detection reactions in parallel. Our strategy achieves equivalent or even superior detection with a single recombinant fusion protein. From the perspective of production, large-scale preparation of a single protein may offer greater economies of scale compared to separately preparing multiple proteins. Meanwhile, our ELISA method simplifies the detection process, affording more convenience. Last but not least, our success with HBV preS1 is just a proof-of-concept test. The dual recombinant strategy proposed in this work provides a universal and easily implementable solution to overcome detection challenges caused by viral variation. This approach can be extended to the development of detection reagents, vaccines, and even therapeutic antibodies for other highly variable viruses (e.g., influenza virus, HIV, HCV, and SARS-CoV-2), opening a new avenue to address the persistent challenges posed by viral evolution. In this work, we have developed an ELISA kit to quantify the preS1 antibody in hepatitis B patients with genotype B or C virus. The key innovation lies in the dual recombinant strategy that joins genotype B preS1 to genotype C preS1 to make B-C-preS1 protein as the coating antigen. We have also engineered a mouse-human chimeric antibody (HB2) capable of recognizing both genotype B and C preS1 as the standard for quantification. A quantitative ELISA kit for HBV preS1 antibody has been developed based on this dual recombinant strategy to extend the patient coverage. It is expected that our ELISA kit covers over 95% of the HBV-infected patients in China. Moreover, the ELISA kit has shown a linear range of 10–100 ng/mL and demonstrated good specificity, accuracy, reproducibility and stability. Not only does the ELISA kit developed in this work hold a good promise for clinical application in China, where it will be a valuable tool for accurate diagnosis and prognosis of HBV, but also the dual recombinant strategy proposed herein may inspire the development of ELISA kits with broader patient coverages for other diseases caused by multiple genotype viruses. Limitations of the study Any strategy has limitations and so is our dual recombinant strategy. Adopting this tandem recombinant strategy requires some prerequisites. First, the protein sequences of various viral genotypes must be known. Second, the strategy remains effective only when the viral mutation rate is not overwhelmingly high. Beyond a certain threshold of mutation rate, its utility may be substantially diminished. Third, optimization is needed for the length of the recombinant protein, the design of linker peptides, and potential spatial hindrance or conformational effects among different epitopes. Additionally, new sequences need to be added to the recombinant protein when new genotype variants of viruses emerge. The cloning and expression of tandem recombinants require some time, though current advances of biotechnology have significantly accelerated this process, making the technical challenges of preparing recombinants manageable. It should also be noted that the sample size of HBV genotype B sera is relatively small in this work. Only 29 of 156 positive sera (approximately 19%) were classified as genotype B. This is because our sera were obtained from northern China, where HBV genotype C is overwhelmingly prevalent. The genotype distribution of our collected sera mirrors the well-established genotype epidemiology of the region, but inevitably reduces the statistical power for assessing assay performance on HBV genotype B. The future use of our kit in southern China would provide better assessment of our kit on HBV genotype B. Resource availability Lead contact Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Zhenning Liu (liu_zhenning@jlu.edu.cn). Materials availability Recombinant antigen and antibody generated in this study will be available on request through the completion of a material transfer agreement. There are restrictions to the availability of the human serum samples due to ethical privacy guidelines in this study. Other materials are in the key resources table. Data and code availability •Data reported in this paper will be shared by the lead contact upon request.•This paper does not report original code.•Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. •Data reported in this paper will be shared by the lead contact upon request. Data reported in this paper will be shared by the lead contact upon request. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Acknowledgments This work was supported by 10.13039/501100012166National Key R&D Program of China (2022YFE0138500 and 2017ZX106080). Author contributions Y.L.: conceptualization, formal analysis, methodology, project administration, writing – original draft; X.W.: investigation, project administration; J.Z.: investigation, visualization; T.C.: data curation, methodology; X.C.: validation, data curation; H.C.: methodology, software; Q.H.: investigation, project administration; W.Z.: project administration, resources; J.N.: writing – review and editing; H.D.: formal analysis, methodology, visualization, writing – original draft; Z.L.: funding acquisition, project administration, resources, supervision, writing – review and editing. Declaration of interests Z.L., Y.L., W.Z., Q.H., and H.C. have patent ZL202210747403.7 issued to Jilin University and Beijing Abace Biotechnology. Z.L., Y.L., W.Z., Q.H., and H.C. have patent ZL202110113419.8 issued to Beijing Abace Biotechnology. Beijing Abace Biotechnology holds the approval from the Food and Drug Administration of China for the ELISA kit developed in this work. W.Z. reports a relationship with Beijing Abace Biotechnology that includes board membership and equity or stocks. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesHorseradish peroxidase (HRP)-conjugated anti-human IgG antibodyLuoyang Baiaotong Experimental Materials CenterCat# C030250; RRID: AB_3756776HRP-conjugated goat anti-mouse IgG antibodyBeijing Solarbio Science & TechnologyCat# SE131; RRID: AB_2797595HB2 antibodyThis paperN/ABacterial and virus strainsE. coli DH5αTsingke BiotechDZC101-8A100Biological samplesSerum samples of patients with hepatitis Bthe First Hospital of Jilin University (Changchun, China)N/AHealthy adult serum samplesthe First Hospital of Jilin University (Changchun, China)N/AChemicals, peptides, and recombinant proteins3,3′,5,5′-tetramethylbenzidine (TMB)Sigma-Aldrich860336phosphate-buffered saline (PBS)Sigma-AldrichP2272Goat serum (GS)Beijing Solarbio Science & TechnologySL038bovine serum albumin (BSA)Bovogen BiologicalsBSAS-NZB-C-preS1This paperN/ACritical commercial assaysThe viral genome DNA/RNA extraction kitYoubao BiologyVT1001DNA gel extraction kitTiangen BiotechDP204The plasmid miniprep kitTiangen BiotechDP103The qualitative preS1 antibody kitShanghai Alpha Biotechnology3400447MycoAlert PLUS Mycoplasma Detection KitLonzaLT07-710Experimental models: Cell linesHEK293F cellsThermo Fisher ScientificA35347Experimental models: Organisms/strainsBALB/c miceVital RiverN/AOligonucleotidesPrimers for nested PCR, see Table S2This paperN/APrimers for recombinant B-C-preS1, see Table S3This paperN/APrimers for anti-preS1 antibodies, see Table S4This paperN/ARecombinant DNADNA sequences of variable regions in HB2 antibody, see Table S1This paperN/AThe pcDNA3.1(−) vectorYoubao BiologyVT1001Software and algorithmsImageJNIHhttps://imagej.nih.gov/ij/download.htmlRRID: SCR_003070OriginOriginLabhttps://www.originlab.comGraphPad PrismGraphPad Softwarehttps://www.graphpad.com/; RRID:SCR_002798 REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesHorseradish peroxidase (HRP)-conjugated anti-human IgG antibodyLuoyang Baiaotong Experimental Materials CenterCat# C030250; RRID: AB_3756776HRP-conjugated goat anti-mouse IgG antibodyBeijing Solarbio Science & TechnologyCat# SE131; RRID: AB_2797595HB2 antibodyThis paperN/ABacterial and virus strainsE. coli DH5αTsingke BiotechDZC101-8A100Biological samplesSerum samples of patients with hepatitis Bthe First Hospital of Jilin University (Changchun, China)N/AHealthy adult serum samplesthe First Hospital of Jilin University (Changchun, China)N/AChemicals, peptides, and recombinant proteins3,3′,5,5′-tetramethylbenzidine (TMB)Sigma-Aldrich860336phosphate-buffered saline (PBS)Sigma-AldrichP2272Goat serum (GS)Beijing Solarbio Science & TechnologySL038bovine serum albumin (BSA)Bovogen BiologicalsBSAS-NZB-C-preS1This paperN/ACritical commercial assaysThe viral genome DNA/RNA extraction kitYoubao BiologyVT1001DNA gel extraction kitTiangen BiotechDP204The plasmid miniprep kitTiangen BiotechDP103The qualitative preS1 antibody kitShanghai Alpha Biotechnology3400447MycoAlert PLUS Mycoplasma Detection KitLonzaLT07-710Experimental models: Cell linesHEK293F cellsThermo Fisher ScientificA35347Experimental models: Organisms/strainsBALB/c miceVital RiverN/AOligonucleotidesPrimers for nested PCR, see Table S2This paperN/APrimers for recombinant B-C-preS1, see Table S3This paperN/APrimers for anti-preS1 antibodies, see Table S4This paperN/ARecombinant DNADNA sequences of variable regions in HB2 antibody, see Table S1This paperN/AThe pcDNA3.1(−) vectorYoubao BiologyVT1001Software and algorithmsImageJNIHhttps://imagej.nih.gov/ij/download.htmlRRID: SCR_003070OriginOriginLabhttps://www.originlab.comGraphPad PrismGraphPad Softwarehttps://www.graphpad.com/; RRID:SCR_002798 Experimental model and study participant details Six Balb/c mice (female, 4 weeks old, 15–20 g) are immunized with recombinant protein. The potential influence of sex on the animal experimental results could not be independently evaluated. All animal experiments are approved by Abace Biotechnology (Approval No. ABACE20180528-002; original approval document in Chinese is available from the authors upon request) and are conducted in accordance with institutional and national guidelines and regulations. HEK293F cells are obtained from Thermo Fisher Scientific (USA), and no additional authentication is performed after receipt. Then, mycoplasma is tested using the MycoAlert PLUS Mycoplasma Detection Kit, confirming that there is no mycoplasma contamination. 156 positive sera (patients) and 66 negative sera (healthy individuals) are obtained from patients with hepatitis B at the First Hospital of Jilin University (Changchun, China). Gender and age have no influence on the experimental results for human serum sample. Those with positive HBV PreS1 antibody are classified as the positive group, while healthy individuals (without HBV PreS1 antibody) are included in the negative group. The study is approved by the Ethics Committee of the First Hospital of Jilin University (Approval No: 19K111-002. The original approval document in Chinese is available from the authors upon request) and is approved in accordance with the principles of the Declaration of Helsinki, and written informed consent is obtained from all participants. Method details Serum genotyping HBV DNA was isolated from sera of Hepatitis B patients and subsequently subjected to nested PCR covering the preS1 and preS2 regions of LHBs as well as the first 186 nucleotides of HBsAg. Non-genotype-specific primers were used in nested PCR to ensure both genotype B and C virus can be amplified (Table S2). Then a mixed set of genotype-specific primers were used to amplify the DNA for sequencing (Table S2). Amplified DNA fragments were sequenced by Sangon Biotech (Beijing, China) with two genotype-specific forward primers. The obtained sequences were BLAST in NCBI to identify HBV genotypes. Preparation of B-C-preS1 recombinant protein A recombinant plasmid containing HBV preS1 sequences of genotypes B and C was constructed by Gibson assembly method. Specifically, HBV DNA extracted from patient sera and characterized as HBV genotypes B and C was amplified using genotype B primers, genotype C primers and overlapping primers (Table S3) by a two-round PCR approach as previously described. The sequence of DNA template used for the amplification of genotype B preS1 is consistent with GenBank: PP831606, whereas the sequence of DNA template used for genotype C preS1 is consistent with GenBank: PP831607. The forward primer to amplify genotype B preS1 contains human serum albumin (HSA) signal peptide sequence followed by Lys and Ala (HSA-KA, 60 nucleotides) and the first 20 nucleotides of genotype B preS1 (GenBank: PP831606). The reverse primer for genotype B preS1 consists of a linker peptide sequence (45 nucleotides), a StrepII-tag sequence (24 nucleotides) and the sequence complementary to the last 20 nucleotides of genotype B preS1 (GenBank: PP831606). The forward primer for the amplification of genotype C preS1 is composed of a linker peptide sequence (30 nucleotides) complementary to the linker sequence in the reverse primer for genotype B preS1 and the first 20 nucleotides of genotype C preS1 (GenBank: PP831607). The reverse primer for genotype C preS1 includes a His6-tag sequence (18 nucleotides) and the sequence complementary to the last 20 nucleotides of genotype C preS1 (GenBank: PP831607). The amplified DNA fragments for genotype B preS1 and genotype C preS1, which contain an overlapping sequence of 30 nucleotides in the linker region, were mixed in the second round of PCR to connect these two sequences. The forward primer for overlapping PCR contains the restriction site of NheI, whereas the reverse primer has the restriction site of NotI. After the second round of overlapping PCR, the amplified DNA fragments were digested with NheI and NotI at 50 °C for 1 h and ligated into the pcDNA3.1(−) vector that had been digested with NheI and NotI at 50 °C for 1 h. Then, the ligated DNA constructs were transformed into competent DH5α cells, and positive clones were selected on ampicillin-containing agar plates. Correct plasmid was confirmed by colony PCR and DNA sequencing. For recombinant protein expression, the verified plasmid was transfected into HEK293F cells at a density of 1 × 106 cells/mL using a plasmid-to-PEI ratio of 2 μg: 5 μg per 100 mL of culture. After 5 days, the culture supernatant was harvested and subjected to two-round affinity chromatography purifications with Ni-NTA followed by Strep-Tactin. Recombinant HBV B-C-preS1 was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting For Wester blotting of recombinant B-C-preS1 with genotype specific antibodies, recombinant B-C-preS1 protein was electrophoresed in 12% SDS-PAGE and then transferred onto polyvinylidene fluoride (PVDF) membranes. After blocking with 5% nonfat milk in TBST buffer for 1 h, the PVDF membranes were incubated with two previously reported genotype specific antibodies (B19 for HBV genotype B and C04 for HBV genotype C) overnight at 4 °C. After washing with TBST, the PVDF membranes then underwent incubation with the secondary antibody. (HRP-conjugated goat anti-mouse IgG antibody, Beijing Solarbio Science & Technology, China) for 60 min at room temperature. After washing with TBST, the PVDF membranes were visualized with a ChemiDoc MP Imaging System (BIO-RAD, USA). Development of mouse-human chimeric preS1 antibody (HB2) Six 4-week-old Balb/c mice were immunized subcutaneously with 5 μg of B-C-preS1 recombinant protein emulsified in Freund’s incomplete adjuvant (1:2 v/v) followed by two rounds of booster immunizations every two weeks. One week after the third round of immunization, peripheral blood was collected and preS1-specific antibodies in sera were detected by ELISA with B-C-preS1-coated microplates (2 μg/mL, 100 μL/well). To identify preS1 antibodies that cross-react with both genotype B and C preS1, genotype B preS1/genotype C preS1 was coated at the same amount (2 μg/mL, 100 μL/well) onto the ELISA plate separately. Mouse sera were added and incubated for 1 h at 37 °C. After 3 washes, HRP-conjugated goat anti-mouse IgG antibody was added to read the OD values. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood containing desired antibody by ficoll density-gradient centrifugation (500 × g, 30 min). PBMCs were stained with fluorescein isothiocyanate (FITC)-labeled B-C-preS1 and phycoerythrin (PE)-conjugated anti-mouse CD19 antibody. Antigen-specific B cells were sorted by flow cytometry. Sorted cells were lysed, and cDNA was synthesized by reverse transcription (25 °C for 10 min, 42 °C for 60 min, 85 °C for 5 min). Variable regions (VH and VL) of mouse anti-preS1 antibodies were amplified by high-fidelity PCR, gel-purified, and cloned into a pcDNA3.1 (−) vector containing human IgG1 Fc. Primers for the heavy chain variable region and light chain variable region of mouse IgG are shown in Table S4. Positive clones verified by sequencing were transfected into HEK293F cells (1 × 106 cells/mL). Supernatants were screened by ELISA against genotype B preS1, genotype C preS1 and B-C-preS1. An antibody cross-reacting with genotype B and C preS1 (HB2) was selected for large-scale expression in HEK293F cells. Expressed HB2 antibody was purified using Protein A agarose beads, eluted with glycine, dialyzed against PBS, and analyzed by 12% SDS-PAGE. Optimization of B-C-preS1 and the detection antibody The optimal combination of the concentration of B-C-preS1 (the coating antigen) and the dilution of HRP-conjugated anti-human IgG (the detection antibody) were determined by the checkerboard titration. Recombinant B-C-preS1 was diluted with coating buffer (PBS at pH = 8.0) to 0.5, 1, 2, 3, 4 and 5 μg/mL and used as 120 μL/well to coat 96-well ELISA plates overnight at 4 °C. B-C-preS1-coated plates was blocked with 4% sucrose and 0.2% BSA for 1 h at 37 °C, and then incubated with HB2 antibody (200 ng/mL) for 1 h at 37 °C. After 3 washes, HRP-conjugated anti-human IgG antibody was added as 100 μL/well at the dilutions of 100k, 150k, 200k, 250k and 300k followed by incubation of 1 h at 37 °C. Following the addition of TMB substrate (100 μL per well) and a 10-min incubation at 37°C, the enzymatic reaction was terminated using 2 M H2SO4. Absorbance was immediately measured at 450 nm and 630 nm using a plate reader. The optical density (OD) for each well was calculated by subtracting the OD630 value from the OD450 value. The optimal concentrations of the B-C-preS1 antigen and detection antibody were then determined by identifying the conditions that yielded the highest positive-to-negative (P/N) signal ratios. Optimization of the coating buffer and coating condition Carbonate-buffered saline (CBS) of various concentrations (0.01 M, 0.02 M, 0.05 M, 0.1 M) at pH = 9.0, as well as PBS of various pH values, were tested as coating buffers. The effects of coating time and temperature on readouts were examined to optimize the coating conditions, including 4 °C for 16 h and 37 °C for 1 h, 2 h, 3 h and 4 h. The determined optimal concentrations of B-C-preS1 and the detection antibody were used following the same protocol as described for the previous experiment. The P/N ratios were used to determine the optimal coating buffer and coating condition. Optimization of the blocking solution and blocking duration Various blocking solutions and blocking durations were tested to improve the signal-to-background ratio. Ten blocking solutions containing 0.2% BSA and 0.25% Tween 20 were used with different concentrations of sucrose and GS. Blocking solutions 1 to 5 contain 4% sucrose and different concentrations of GS (2%, 4%, 6%, 8%, and 10% respectively), while blocking solutions 6 to 10 contain 8% sucrose and various concentrations of GS (2%, 4%, 6%, 8%, and 10% respectively). The coated ELISA plates were blocked at 37 °C for 1 h, 2 h, 3 h and 4 h. The measurements were performed with the optimal concentrations and conditions determined in the previous optimization experiments following the same protocol. The P/N ratios were used to determine the optimal blocking solution and blocking duration. Optimization of the sample dilution buffer and incubation time Sample dilution buffer and incubation time were optimized to improve stability and signal-to-background ratio of the ELISA kit. As shown in Table S5, 15 sample dilution buffers containing 0.1% Proclin300 but different concentrations of Tween 20 and GS were tested. HB2 was diluted as 1:10 in each dilution buffer and incubated in coated ELISA plate at 37 °C for 0.5, 1, 1.5 and 2 h, 100 μL/well. The measurements were performed with the optimal concentrations and conditions determined in the previous optimization experiments following the same protocol. The P/N ratios were used to determine the optimal sample dilution buffer and incubation time. Optimization of the dilution buffer and incubation time for HRP-conjugated anti-human IgG 1 × PBS solutions containing 2%, 4%, 8%, and 10% NaCl were used to dilute HRP-conjugated anti-human IgG as 1:200000. The diluted antibody solutions were incubated in ELISA plate at 37 °C for 0.5 h, 1 h, 1.5 h, 2 h, 100 μL/well. The measurements were performed with the optimal concentrations and conditions determined in the previous optimization experiments following the same protocol. The P/N ratios were used to test the optimal dilution buffer and incubation time for HRP-conjugated anti-human IgG. Performance evaluation for the quantitative ELISA kit for HBV preS1 antibody The intra- and inter-assay coefficients of variation (CVs) were calculated using three positive serum samples. For the intra-assay CV, each serum was tested in 12 replicate wells within a single assay run. To determine the inter-assay CV, the same set of sera was assayed across three independently manufactured batches of ELISA kits. CV = mean/standard deviation (Table 1). To evaluate the accuracy of the quantification of preS1 antibody in patient sera, the standard HB2 antibody was used as the internal reference within patient sera in ELISA measurements. Three patient sera with different concentrations of HBV virus were mixed with negative control serum (without HB2) or serum containing a known amount of HB2. The levels of preS1 antibody were measured by the quantitative ELISA kit to calculate the recovery rate according to the formula (Table 2).Recovery(%)=C(measuredlevel)C(expectedlevel)×100% For cross-reactivity tests, hepatitis A virus (HAV), hepatitis C virus (HCV), HBV genotype A (HBV-A) and HBV genotype D (HBV-D) were obtained from the commercial kits (GBI Biotech, Beijing, China). All assays followed the standard operating procedure established for the home-made ELISA kit. The stability was assessed under several conditions, including accelerated, in-use, and simulated transportation scenarios, as well as during real-time storage. Standards and three sera were tested in triplicates. The threshold for these stability tests was set as 80–120% of the HBV preS1 antibody concentrations measured by freshly prepared kits. Tests with commercial kits for preS1 antibody The home-made ELISA kit was compared with two commercial kits for preS1 antibody. One is a qualitative preS1 antibody kit from Shanghai Alpha Biotechnology and the other is a quantitative preS1 antibody kit from Shanghai Yueyan Biotech. Quantification and statistical analysis Data are presented as mean ± standard deviation (SD), error bars represent SD for three independent experiments, unless otherwise indicated in the Figure Legends. Construction and analysis of the receiver operating characteristic (ROC) curves were performed using GraphPad Prism (Version 8.3.0). Origin (2024) was used for statistical analyses. Significance for the differences were determined by One-way ANOVA with Tukey’s post-test. The significance level was α = 0.05, and p values are reported: p value <0.05 demonstrates significance; p value <0.01 demonstrates high significance; p value <0.001 demonstrates very high significance.